Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Actas urol. esp ; 47(4): 250-258, mayo 2023. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-219981

RESUMO

Introducción Durante 2019 se produjo una escasez mundial de cepas de BCG para instilación intravesical, limitando la disponibilidad de esquemas de dosis completas para la fase de mantenimiento. El objetivo principal del estudio fue analizar el impacto del desabastecimiento de BCG sobre la recidiva tumoral en nuestro centro. Los criterios de valoración secundarios incluyeron las tasas de recidiva y supervivencia libre de progresión y las características específicas de la recidiva tumoral. Métodos Estudio de cohortes retrospectivo que incluye a 158 sujetos (64 tratados durante 2019 y 94 durante 2017) con cáncer vesical no infiltrante de alto riesgo y tratados con una combinación de resección transuretral de vejiga (RTUV) seguida de instilación intravesical de BCG adyuvante en un hospital terciario de España. Se analizaron las características basales de ambos grupos. El periodo transcurrido hasta el evento de interés (recaída; incluyendo recurrencia o progresión) se estimó con el análisis de supervivencia de Kaplan-Meier. Las tasas de supervivencia libre de enfermedad se analizaron mediante un modelo multivariable de regresión de Cox de riesgos proporcionales. Resultados La mediana del tiempo de seguimiento fue de 24 y 50 meses en las muestras de 2019 y 2017, respectivamente, con una mediana del número de instilaciones de 8 y 12, respectivamente. Se observó una mediana de tiempo hasta la recurrencia de 285 días (145-448) durante 2019 y de 382 días (215-567) en 2017 (log-rank p=0,025). Un análisis multivariable adicional reveló un HR proporcional para la tasa de supervivencia libre de enfermedad de 1,87 (IC 95%: 1,04-3,37 p=0,036). No se observaron diferencias estadísticamente significativas en las características de la recaída tumoral (AU)


Introduction During 2019 there was a worldwide shortage of BCG strains for intravesical instillation, limiting the availability of full dose schemes for maintenance courses. The main objective was to analyze the impact on tumoral relapse secondary to BCG shortage in our center. Secondary outcomes included recurrence and progression–free survival rates and tumoral relapse specific characteristics. Methods Retrospective cohort study including 158 subjects (64 treated during 2019 and 94 during 2017) with high-risk non-muscle invasive bladder cancer and treated with a combination of Transurethral bladder resection (TURB) followed by adjuvant intravesical instillation with BCG in a tertiary hospital in Spain. Basal characteristics of both groups were analyzed. Times to event of interest (relapse; including recurrence and/or progression) were estimated with Kaplan-Meier survival analysis. Disease-free survival rates were analyzed using a multivariable Cox regression model of proportional hazards. Results Median follow-up in the 2019 sample was 24 months and 50 months in the 2017 group with a median number of instillations of 8 and 12 respectively. Median time to relapse of 285 days (145-448) during 2019 and 382 days (215-567) in 2017 were observed (logRank P=.025). Further multivariable analysis revealed a proportional hazard ratio (HR) for disease-free survival rate of 1.87 (95% CI: 1.04-3.37 P=.036). No statistically significant differences in tumoral relapse characteristics were observed. Conclusion BCG shortage and subsequent reduced-dose schemes used for intravesical instillation due to limited availability, increase early tumoral relapse rates. These findings are consistent with available evidence, showing the need for full-dose BCG courses (AU)


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/patologia , Vacina BCG/provisão & distribuição , Vacina BCG/administração & dosagem , Estudos Retrospectivos , Estudos de Coortes , Recidiva Local de Neoplasia , Intervalo Livre de Progressão , Estimativa de Kaplan-Meier , Seguimentos
2.
Actas Urol Esp (Engl Ed) ; 47(4): 250-258, 2023 05.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-36754206

RESUMO

INTRODUCTION: During 2019 there was a worldwide shortage of BCG strains for intravesical instillation, limiting the availability of full dose schemes for maintenance courses. The main objective was to analyze the impact on tumoral relapse secondary to BCG shortage in our center. Secondary outcomes included recurrence and progression-free survival rates and tumoral relapse specific characteristics. METHODS: Retrospective cohort study including 158 subjects (64 treated during 2019 and 94 during 2017) with high-risk non-muscle invasive bladder cancer and treated with a combination of Transurethral bladder resection (TURB) followed by adjuvant intravesical instillation with BCG in a tertiary hospital in Spain. Basal characteristics of both groups were analyzed. Times to event of interest (relapse; including recurrence and/or progression) were estimated with Kaplan-Meier survival analysis. Disease-free survival rates were analyzed using a multivariable Cox regression model of proportional hazards. RESULTS: Median follow-up in the 2019 sample was 24 months and 50 months in the 2017 group with a median number of instillations of 8 and 12 respectively. Median time to relapse of 285 days (145-448) during 2019 and 382 days (215-567) in 2017 were observed (logRank p = 0.025). Further multivariable analysis revealed a proportional hazard ratio (HR) for disease-free survival rate of 1.87 (95% CI: 1.04-3.37 p = 0.036). No statistically significant differences in tumoral relapse characteristics were observed. CONCLUSION: BCG shortage and subsequent reduced-dose schemes used for intravesical instillation due to limited availability, increase early tumoral relapse rates. These findings are consistent with available evidence, showing the need for full-dose BCG courses.


Assuntos
Neoplasias da Bexiga Urinária , Bexiga Urinária , Humanos , Administração Intravesical , Estudos Retrospectivos , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/cirurgia , Neoplasias da Bexiga Urinária/patologia , Recidiva , Vacina BCG/uso terapêutico
3.
Talanta ; 117: 492-504, 2013 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-24209372

RESUMO

The application of the Multivariate Curve Resolution by Alternating Least Squares (MCR-ALS) method to model and control blend processes of pharmaceutical formulations is assessed. Within the MCR-ALS framework, different data analysis approaches have been tested depending on the objective of the study, i.e., knowing the effect of different factors in the evolution of the blending process (modeling) or detecting the blend end-point and monitoring the concentration of the different species during and at the end of the process (control). Data analysis has been carried out studying multiple blending runs simultaneously taking advantage of the multiset mode of the MCR-ALS method. During the ALS optimization, natural constraints, such as non-negativity (spectral and concentration directions) have been applied for blend modeling. When blending control is the main purpose, a variant of the MCR-ALS algorithm with correlation constraint in the concentration direction has been additionally used. This constraint incorporates an internal calibration procedure, which relates resolved concentration values (in arbitrary units) with the real reference concentration values in the calibration samples (known references) providing values in real concentration scale in the final MCR-ALS results. Two systems consisting of pharmaceutical mixtures of an active principle (acetaminophen) with two or four excipients have been investigated. In the first case, MCR results allowed the description of the evolution of the individual compounds and the assessment of some physical effects in the blending process. In the second case, MCR analysis allowed the detection of the end-point of the process and the assessment of the effects linked to variations in the concentration level of the compounds.


Assuntos
Acetaminofen/química , Carboximetilcelulose Sódica/química , Celulose/química , Excipientes/química , Lactose/química , Ácidos Esteáricos/química , Algoritmos , Calibragem , Composição de Medicamentos/estatística & dados numéricos , Humanos , Análise dos Mínimos Quadrados , Análise Multivariada , Valores de Referência , Espectrofotometria Infravermelho
4.
J Biomol Struct Dyn ; 21(2): 267-78, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12956610

RESUMO

A procedure is described for the complete resolution of concentration profiles of oligonucleotide triplexes as a function of pH and temperature. The pH and temperature ranges at which triplexes are present and the relative concentrations of all the species involved in acid-base and conformational equilibria are successfully estimated from Multivariate Curve Resolution analysis of UV absorbance spectra recorded along acid-base titrations and melting experiments of single stranded, hairpin and their mixtures. The dependence of formation constants upon pH was successfully estimated. The hairpin h26 (5'-GAAGGAGGAGA-TTTT-TCTCCTCCTTC-3'), and the single stranded oligonucleotides s11CT (5'-CTTCCTCCTCT-3'), s11AG (5'-AGAGGAGGAAG-3') and s11TG (5'-TGTGGTGGTTG-3') were synthesized and their protonation and conformational equilibria were studied in detail. The procedure was shown to be especially useful for the study of triplexes with a low hypochromism upon formation.


Assuntos
DNA/química , Conformação de Ácido Nucleico , Desnaturação de Ácido Nucleico , Oligonucleotídeos/química , Sequência de Bases , Concentração de Íons de Hidrogênio , Análise Multivariada , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...